MedTrace Logo

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

NCT06536868 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-24

No results posted yet for this study

Summary

This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.

Conditions

  • Extensive-stage Small-cell Lung Cancer

Interventions

DRUG

Tislelizumab

Tislelizumab infusion will be administered for 2 years (200mg, day1, Q3W).

DRUG

Etoposide

Etoposide intravenous infusion will be administered during the induction phase (100mg/㎡, day1-3 Q3W for 4 cycles).

DRUG

Carboplatin or Cisplatin

Carboplatin or Cisplatin intravenous infusion will be administered during the induction phase (Carboplatin AUC5, Q3W for 4 cycles; Cisplatin 75mg/㎡, Q3W for 4 cycles).

RADIATION

Thoracic radiotherapy

IMRT 30-45Gy/10-15f

Sponsors & Collaborators

  • Second Hospital of Shanxi Medical University

    lead OTHER

Principal Investigators

  • Gang Jin, Dr. · Second Hospital of Shanxi Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06536868 on ClinicalTrials.gov